vs
Astrana Health, Inc.（ASTH）与CF Industries（CF）财务数据对比。点击上方公司名可切换其他公司
CF Industries的季度营收约是Astrana Health, Inc.的2.0倍（$1.9B vs $950.5M），CF Industries净利率更高（26.4% vs 0.7%，领先25.8%），Astrana Health, Inc.同比增速更快（42.9% vs 22.8%），CF Industries自由现金流更多（$313.0M vs $-6.0M），过去两年Astrana Health, Inc.的营收复合增速更高（53.3% vs 12.8%）
Astrana Health是一家总部位于美国的价值导向型医疗服务提供商，主要服务全美符合联邦医保资格的老年群体，提供上门初级护理、慢性病管理及护理协调服务，致力于提升患者健康水平、降低不必要的医疗支出。
CF Industries Holdings Inc.是美国知名农用肥料生产及分销商，1946年成立时名为中央农民肥料公司，总部位于芝加哥郊区的伊利诺伊州诺斯布鲁克。公司主营氨、尿素、硝酸铵等肥料产品，最初为区域农业供应合作社联盟，成立56年后完成股份化改制，转为公开上市企业。
ASTH vs CF — 直观对比
营收规模更大
CF
是对方的2.0倍
$950.5M
营收增速更快
ASTH
高出20.1%
22.8%
净利率更高
CF
高出25.8%
0.7%
自由现金流更多
CF
多$318.9M
$-6.0M
两年增速更快
ASTH
近两年复合增速
12.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $950.5M | $1.9B |
| 净利润 | $6.6M | $495.0M |
| 毛利率 | — | 40.9% |
| 营业利润率 | 1.9% | 33.0% |
| 净利率 | 0.7% | 26.4% |
| 营收同比 | 42.9% | 22.8% |
| 净利润同比 | 184.4% | 26.3% |
| 每股收益（稀释后） | $0.12 | $2.56 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTHCF
| Q4 25 | $950.5M | $1.9B | ||
| Q3 25 | $956.0M | $1.7B | ||
| Q2 25 | $654.8M | $1.9B | ||
| Q1 25 | $620.4M | $1.7B | ||
| Q4 24 | $665.2M | $1.5B | ||
| Q3 24 | $478.7M | $1.4B | ||
| Q2 24 | $486.3M | $1.6B | ||
| Q1 24 | $404.4M | $1.5B |
净利润ASTHCF
| Q4 25 | $6.6M | $495.0M | ||
| Q3 25 | $373.0K | $460.0M | ||
| Q2 25 | $9.4M | $492.0M | ||
| Q1 25 | $6.7M | $351.0M | ||
| Q4 24 | $-7.8M | $392.0M | ||
| Q3 24 | $16.1M | $341.0M | ||
| Q2 24 | $19.2M | $506.0M | ||
| Q1 24 | $14.8M | $238.0M |
毛利率ASTHCF
| Q4 25 | — | 40.9% | ||
| Q3 25 | — | 38.1% | ||
| Q2 25 | — | 39.9% | ||
| Q1 25 | — | 34.4% | ||
| Q4 24 | — | 34.4% | ||
| Q3 24 | — | 32.4% | ||
| Q2 24 | — | 43.2% | ||
| Q1 24 | — | 27.8% |
营业利润率ASTHCF
| Q4 25 | 1.9% | 33.0% | ||
| Q3 25 | 2.0% | 35.0% | ||
| Q2 25 | 3.1% | 34.3% | ||
| Q1 25 | 3.3% | 27.4% | ||
| Q4 24 | 0.1% | 28.9% | ||
| Q3 24 | 5.9% | 26.6% | ||
| Q2 24 | 6.2% | 40.6% | ||
| Q1 24 | 7.5% | 20.6% |
净利率ASTHCF
| Q4 25 | 0.7% | 26.4% | ||
| Q3 25 | 0.0% | 27.7% | ||
| Q2 25 | 1.4% | 26.0% | ||
| Q1 25 | 1.1% | 21.1% | ||
| Q4 24 | -1.2% | 25.7% | ||
| Q3 24 | 3.4% | 24.9% | ||
| Q2 24 | 3.9% | 32.2% | ||
| Q1 24 | 3.7% | 16.2% |
每股收益（稀释后）ASTHCF
| Q4 25 | $0.12 | $2.56 | ||
| Q3 25 | $0.01 | $2.19 | ||
| Q2 25 | $0.19 | $2.37 | ||
| Q1 25 | $0.14 | $1.85 | ||
| Q4 24 | $-0.14 | $1.86 | ||
| Q3 24 | $0.33 | $1.55 | ||
| Q2 24 | $0.40 | $2.30 | ||
| Q1 24 | $0.31 | $1.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $429.5M | — |
| 总债务越低越好 | — | $3.2B |
| 股东权益账面价值 | $779.3M | $4.8B |
| 总资产 | $2.2B | $14.1B |
| 负债/权益比越低杠杆越低 | — | 0.66× |
8季度趋势，按日历期对齐
现金及短期投资ASTHCF
| Q4 25 | $429.5M | — | ||
| Q3 25 | $463.4M | — | ||
| Q2 25 | $342.1M | — | ||
| Q1 25 | $260.9M | — | ||
| Q4 24 | $290.8M | — | ||
| Q3 24 | $350.3M | — | ||
| Q2 24 | $327.7M | — | ||
| Q1 24 | $337.3M | — |
总债务ASTHCF
| Q4 25 | — | $3.2B | ||
| Q3 25 | — | $3.0B | ||
| Q2 25 | — | $3.0B | ||
| Q1 25 | — | $3.0B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | — | $3.0B | ||
| Q2 24 | — | $3.0B | ||
| Q1 24 | — | $3.0B |
股东权益ASTHCF
| Q4 25 | $779.3M | $4.8B | ||
| Q3 25 | $775.5M | $4.8B | ||
| Q2 25 | $765.5M | $5.0B | ||
| Q1 25 | $745.4M | $4.8B | ||
| Q4 24 | $712.7M | $5.0B | ||
| Q3 24 | $704.6M | $5.2B | ||
| Q2 24 | $678.9M | $5.5B | ||
| Q1 24 | $653.5M | $5.4B |
总资产ASTHCF
| Q4 25 | $2.2B | $14.1B | ||
| Q3 25 | $2.2B | $14.2B | ||
| Q2 25 | $1.4B | $13.8B | ||
| Q1 25 | $1.3B | $13.3B | ||
| Q4 24 | $1.4B | $13.5B | ||
| Q3 24 | $1.3B | $13.8B | ||
| Q2 24 | $1.3B | $13.8B | ||
| Q1 24 | $1.2B | $13.9B |
负债/权益比ASTHCF
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.61× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 0.62× | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | — | 0.57× | ||
| Q2 24 | — | 0.54× | ||
| Q1 24 | — | 0.55× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.9M | $539.0M |
| 自由现金流经营现金流 - 资本支出 | $-6.0M | $313.0M |
| 自由现金流率自由现金流/营收 | -0.6% | 16.7% |
| 资本支出强度资本支出/营收 | 0.3% | 12.1% |
| 现金转化率经营现金流/净利润 | -0.44× | 1.09× |
| 过去12个月自由现金流最近4个季度 | $104.5M | $1.8B |
8季度趋势，按日历期对齐
经营现金流ASTHCF
| Q4 25 | $-2.9M | $539.0M | ||
| Q3 25 | $10.0M | $1.1B | ||
| Q2 25 | $90.9M | $563.0M | ||
| Q1 25 | $16.6M | $586.0M | ||
| Q4 24 | $-10.9M | $420.0M | ||
| Q3 24 | $34.0M | $931.0M | ||
| Q2 24 | $23.2M | $475.0M | ||
| Q1 24 | $6.0M | $445.0M |
自由现金流ASTHCF
| Q4 25 | $-6.0M | $313.0M | ||
| Q3 25 | $7.4M | $717.0M | ||
| Q2 25 | $89.5M | $318.0M | ||
| Q1 25 | $13.6M | $454.0M | ||
| Q4 24 | $-13.5M | $223.0M | ||
| Q3 24 | $31.7M | $792.0M | ||
| Q2 24 | $20.4M | $391.0M | ||
| Q1 24 | $5.6M | $347.0M |
自由现金流率ASTHCF
| Q4 25 | -0.6% | 16.7% | ||
| Q3 25 | 0.8% | 43.2% | ||
| Q2 25 | 13.7% | 16.8% | ||
| Q1 25 | 2.2% | 27.3% | ||
| Q4 24 | -2.0% | 14.6% | ||
| Q3 24 | 6.6% | 57.8% | ||
| Q2 24 | 4.2% | 24.9% | ||
| Q1 24 | 1.4% | 23.6% |
资本支出强度ASTHCF
| Q4 25 | 0.3% | 12.1% | ||
| Q3 25 | 0.3% | 20.9% | ||
| Q2 25 | 0.2% | 13.0% | ||
| Q1 25 | 0.5% | 7.9% | ||
| Q4 24 | 0.4% | 12.9% | ||
| Q3 24 | 0.5% | 10.1% | ||
| Q2 24 | 0.6% | 5.3% | ||
| Q1 24 | 0.1% | 6.7% |
现金转化率ASTHCF
| Q4 25 | -0.44× | 1.09× | ||
| Q3 25 | 26.69× | 2.31× | ||
| Q2 25 | 9.65× | 1.14× | ||
| Q1 25 | 2.48× | 1.67× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | 2.11× | 2.73× | ||
| Q2 24 | 1.21× | 0.94× | ||
| Q1 24 | 0.40× | 1.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
CF
| Ammonia | $591.0M | 32% |
| UAN | $493.0M | 26% |
| Urea | $372.0M | 20% |
| Other | $244.0M | 13% |
| Other Products | $147.0M | 8% |
| Ammonium Nitrate Segment | $25.0M | 1% |
